{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:01:20Z","timestamp":1778846480510,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"TTC Oncology"},{"name":"Engdahl Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10549-020-05787-z","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T06:54:52Z","timestamp":1595400892000},"page":"617-627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4\/6 inhibitor therapy"],"prefix":"10.1007","volume":"183","clinical-trial-number":[{"clinical-trial-number":"nct03201913","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Arkadiusz Z.","family":"Dudek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth L.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasgit C.","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randolph W.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Tonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R. J.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Venuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"O\u2019Regan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"issue":"1","key":"5787_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G, Cerbone L, Zanardi E, Messina M, Boccardo F (2018) CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 172(1):9\u201321","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"5787_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/cam4.2095","volume":"8","author":"J Li","year":"2019","unstructured":"Li J, Wang Z, Shao Z (2019) Fulvestrant in the treatment of hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. Cancer Med 8(5):1943\u20131957","journal-title":"Cancer Med"},{"key":"5787_CR3","first-page":"45","volume":"12","author":"M Iorfida","year":"2020","unstructured":"Iorfida M, Mazza M, Munzone E (2020) Fulvestrant in Combination with CDK4\/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. Breast Cancer (Dove Med Press) 12:45\u201356","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"11","key":"5787_CR4","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1535-7163.MCT-14-0319","volume":"13","author":"ME Molloy","year":"2014","unstructured":"Molloy ME, White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H, Maximov PY, Jordan VC, Thatcher GR et al (2014) Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther 13(11):2515\u20132526","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5787_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/acs.jmedchem.5b01276","volume":"59","author":"R Xiong","year":"2016","unstructured":"Xiong R, Patel HK, Gutgesell LM, Zhao J, Delgado-Rivera L, Pham TND, Zhao H, Carlson K, Martin T, Katzenellenbogen JA et al (2016) Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. J Med Chem 59(1):219\u2013237","journal-title":"J Med Chem"},{"issue":"3","key":"5787_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1677\/erc.0.0100389","volume":"10","author":"HJ Mackay","year":"2003","unstructured":"Mackay HJ, Twelves CJ (2003) Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 10(3):389\u2013396","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"5787_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/jcp.2006.041616","volume":"60","author":"JW Assender","year":"2007","unstructured":"Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI (2007) Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 60(11):1216\u20131221","journal-title":"J Clin Pathol"},{"key":"5787_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1476-4598-9-76","volume":"9","author":"GK Lonne","year":"2010","unstructured":"Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C (2010) PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 9:76","journal-title":"Mol Cancer"},{"issue":"5","key":"5787_CR9","first-page":"2028","volume":"6","author":"K Yao","year":"2000","unstructured":"Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC (2000) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6(5):2028\u20132036","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5787_CR10","first-page":"3156","volume":"7","author":"MJ Chisamore","year":"2001","unstructured":"Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA (2001) Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7(10):3156\u20133165","journal-title":"Clin Cancer Res"},{"key":"5787_CR11","unstructured":"Services USDoHaH: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 https:\/\/www.evsncinihgov\/ftp1\/CTCAE\/CTCAE_403 June 14, 2010."},{"issue":"2","key":"5787_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"9","key":"5787_CR13","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.bjc.6600923","volume":"88","author":"DA Tonetti","year":"2003","unstructured":"Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S (2003) Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 88(9):1400\u20131402","journal-title":"Br J Cancer"},{"key":"5787_CR14","doi-asserted-by":"publisher","first-page":"740353","DOI":"10.1155\/2012\/740353","volume":"2012","author":"DA Tonetti","year":"2012","unstructured":"Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS (2012) PKCalpha and ERbeta Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int J Breast Cancer 2012:740353","journal-title":"Int J Breast Cancer"},{"issue":"3","key":"5787_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/85.3.200","volume":"85","author":"DC Allred","year":"1993","unstructured":"Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85(3):200\u2013206","journal-title":"J Natl Cancer Inst"},{"issue":"10226","key":"5787_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817\u2013827","journal-title":"Lancet"},{"issue":"1","key":"5787_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S et al (2020) PTEN Loss Mediates Clinical Cross-Resistance to CDK4\/6 and PI3Kalpha Inhibitors in Breast Cancer. Cancer Discov 10(1):72\u201385","journal-title":"Cancer Discov"},{"issue":"7","key":"5787_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jama.2009.1204","volume":"302","author":"MJ Ellis","year":"2009","unstructured":"Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302(7):774\u2013780","journal-title":"JAMA"},{"issue":"4","key":"5787_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/bcr436","volume":"4","author":"JN Ingle","year":"2002","unstructured":"Ingle JN (2002) Estrogen as therapy for breast cancer. Breast Cancer Res 4(4):133\u2013136","journal-title":"Breast Cancer Res"},{"issue":"2","key":"5787_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1006185805079","volume":"54","author":"PP Peethambaram","year":"1999","unstructured":"Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL (1999) Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54(2):117\u2013122","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5787_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/00000421-198504000-00004","volume":"8","author":"H Matelski","year":"1985","unstructured":"Matelski H, Greene R, Huberman M, Lokich J, Zipoli T (1985) Randomized trial of estrogen vs tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 8(2):128\u2013133","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"5787_CR22","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/ERC-14-0448","volume":"22","author":"VC Jordan","year":"2015","unstructured":"Jordan VC (2015) The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer 22(1):R1\u201331","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"5787_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.6004\/jnccn.2015.0106","volume":"13","author":"RT Chlebowski","year":"2015","unstructured":"Chlebowski RT, Aragaki AK, Anderson GL (2015) Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. J Natl Compr Canc Netw 13(7):917\u2013924","journal-title":"J Natl Compr Canc Netw"},{"issue":"18","key":"5787_CR24","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.ejca.2015.08.028","volume":"51","author":"G Zucchini","year":"2015","unstructured":"Zucchini G, Armstrong AC, Wardley AM, Wilson G, Misra V, Seif M, Ryder WD, Cope J, Blowers E, Howell A et al (2015) A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. Eur J Cancer 51(18):2725\u20132731","journal-title":"Eur J Cancer"},{"key":"5787_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.maturitas.2016.10.010","volume":"95","author":"HJ Coelingh Bennink","year":"2017","unstructured":"Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J (2017) The use of high-dose estrogens for the treatment of breast cancer. Maturitas 95:11\u201323","journal-title":"Maturitas"},{"issue":"10","key":"5787_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","volume":"41","author":"MS Roberts","year":"2002","unstructured":"Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41(10):751\u2013790","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"5787_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/11319320-000000000-00000","volume":"49","author":"NM Davies","year":"2010","unstructured":"Davies NM, Takemoto JK, Brocks DR, Yanez JA (2010) Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 49(6):351\u2013377","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"5787_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1208\/s12248-014-9693-5","volume":"17","author":"K Ogungbenro","year":"2015","unstructured":"Ogungbenro K, Pertinez H, Aarons L (2015) Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying. AAPS J 17(1):227\u2013236","journal-title":"AAPS J"},{"issue":"1","key":"5787_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13058-019-1149-5","volume":"21","author":"L Rossi","year":"2019","unstructured":"Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C et al (2019) Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Res 21(1):71","journal-title":"Breast Cancer Res"},{"issue":"8","key":"5787_CR30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/carcin\/bgl002","volume":"27","author":"X Lin","year":"2006","unstructured":"Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA (2006) Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 27(8):1538\u20131546","journal-title":"Carcinogenesis"},{"key":"5787_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fonc.2014.00087","volume":"4","author":"JA Wallace","year":"2014","unstructured":"Wallace JA, Pitarresi JR, Sharma N, Palettas M, Cuitino MC, Sizemore ST, Yu L, Sanderlin A, Rosol TJ, Mehta KD et al (2014) Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis. Front Oncol 4:87","journal-title":"Front Oncol"},{"issue":"4","key":"5787_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Ponten","year":"2008","unstructured":"Ponten F, Jirstrom K, Uhlen M (2008) The Human Protein Atlas\u2013a tool for pathology. J Pathol 216(4):387\u2013393","journal-title":"J Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05787-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05787-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:55:24Z","timestamp":1628610924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05787-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5787"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05787-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AZD serves as Chief Medical Officer and obtained honoraria from TTC Oncology and Vanquish Oncology. AZD has received honoraria for consulting work from EMD Serono. AZD has equity in TTC Oncology, IGF Oncology, Squarex, and Martell Diagnostic Laboratories. AZD reports research funding to institutions from Merck, and Eli Lilly. DAT and GRJT have equity in TTC Oncology. RPV has received honoraria from TTC Oncology. RMO serves as an advisor for Lilly, PUMA, Novartis, Genomic Health and Biotheranostics and receives grant support from PUMA, Novartis, Seattle Genetics, and Eisai. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This clinical trial was approved by the Institutional Review Board at the participating institutions. It was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}